What is the management of hyponatremia in patients with underlying conditions such as heart failure, liver disease, or Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)?

Management of Hyponatremia

Initial Assessment and Classification

Hyponatremia management depends critically on three factors: volume status (hypovolemic, euvolemic, or hypervolemic), symptom severity, and chronicity (acute <48 hours vs chronic >48 hours). 1

• Obtain serum and urine osmolality, urine sodium, urine electrolytes, serum uric acid, and assess extracellular fluid volume status to determine the underlying cause 1
• Hyponatremia is defined as serum sodium <135 mmol/L, with clinically significant hyponatremia typically <130-131 mmol/L 1, 2
• Physical examination for volume status has poor accuracy (sensitivity 41.1%, specificity 80%), so laboratory values are essential 1

---

Management Based on Symptom Severity

Severe Symptomatic Hyponatremia (Seizures, Coma, Altered Mental Status)

Administer 3% hypertonic saline immediately with a target correction of 6 mmol/L over 6 hours or until severe symptoms resolve. 1, 3, 4

• Give 100 mL boluses of 3% saline over 10 minutes, repeatable up to three times at 10-minute intervals until symptoms improve 1
• Transfer to ICU for close monitoring 1, 3
• Monitor serum sodium every 2 hours during initial correction 1, 3
• Total correction must not exceed 8 mmol/L in 24 hours to prevent osmotic demyelination syndrome 1, 3, 4, 5
• For high-risk patients (advanced liver disease, alcoholism, malnutrition), limit correction to 4-6 mmol/L per day 1, 3, 5

Mild to Moderate Symptomatic or Asymptomatic Hyponatremia

Treatment depends on volume status and underlying etiology 1

---

Management Based on Underlying Condition

SIADH (Euvolemic Hyponatremia)

Fluid restriction to 1 L/day is the cornerstone of treatment for mild to moderate SIADH. 1, 3, 4

Diagnostic criteria for SIADH: 3, 4

• Hypotonic hyponatremia (serum sodium <134 mEq/L, plasma osmolality <275 mOsm/kg)
• Inappropriately high urine osmolality (>500 mOsm/kg)
• Urine sodium >20-40 mEq/L
• Euvolemic state (no edema, no orthostatic hypotension, normal skin turgor)
• Normal thyroid, adrenal, and renal function

Treatment algorithm: 1, 3, 4

• First-line: Fluid restriction to 1 L/day (correction rate averages 1.0 mEq/L/day) 4
• Second-line (if fluid restriction fails): Add oral sodium chloride 100 mEq three times daily 1
• Third-line pharmacological options: 1, 3, 4, 6
  • Urea 0.25-0.50 g/kg/day (highly effective, well-tolerated long-term, though distaste is common in 54% of patients) 4
  • Demeclocycline (induces nephrogenic diabetes insipidus) 3, 4
  • Tolvaptan 15 mg once daily, titrate to 30-60 mg (vasopressin receptor antagonist) 1, 5

Tolvaptan-specific considerations: 5

• Must be initiated and re-initiated in hospital with close sodium monitoring
• Starting dose 15 mg once daily, increase to 30 mg after at least 24 hours, maximum 60 mg daily
• Do not use for more than 30 days to minimize liver injury risk
• Contraindicated with strong CYP3A inhibitors
• Monitor sodium at 0,6,24, and 48 hours to prevent overly rapid correction

Heart Failure (Hypervolemic Hyponatremia)

Implement fluid restriction to 1-1.5 L/day for serum sodium <125 mmol/L. 1

• Discontinue diuretics temporarily if sodium <125 mmol/L 1
• Avoid hypertonic saline unless life-threatening symptoms are present, as it may worsen fluid overload 1
• For persistent severe hyponatremia despite fluid restriction and guideline-directed medical therapy, consider vasopressin antagonists (tolvaptan) in the short term 1
• The benefit of fluid restriction to reduce congestive symptoms is uncertain in heart failure patients 1

Liver Disease/Cirrhosis (Hypervolemic Hyponatremia)

Implement fluid restriction to 1-1.5 L/day for serum sodium <125 mmol/L, combined with albumin infusion. 1

• Discontinue diuretics temporarily if sodium <125 mmol/L 1
• Albumin infusion alongside fluid restriction improves hyponatremia in cirrhotic patients 1
• Avoid hypertonic saline unless life-threatening symptoms are present 1
• Critical correction rate: 4-6 mmol/L per day maximum, never exceeding 8 mmol/L in 24 hours 1
• Cirrhotic patients have higher risk of osmotic demyelination syndrome 1
• Hyponatremia in cirrhosis increases risk of spontaneous bacterial peritonitis (OR 3.40), hepatorenal syndrome (OR 3.45), and hepatic encephalopathy (OR 2.36) 1
• Important principle: It is sodium restriction, not fluid restriction, that results in weight loss as fluid passively follows sodium 1

---

Critical Safety Considerations

Osmotic Demyelination Syndrome Prevention

The single most important principle: never exceed 8 mmol/L correction in 24 hours. 1, 3, 4, 5, 2

• For high-risk patients (advanced liver disease, alcoholism, malnutrition, severe hyponatremia), limit to 4-6 mmol/L per day 1, 3, 5
• Osmotic demyelination presents with dysarthria, dysphagia, oculomotor dysfunction, quadriparesis, typically 2-7 days after rapid correction 1
• If overcorrection occurs, immediately discontinue current fluids, switch to D5W, and consider desmopressin to relower sodium 1

Monitoring Requirements

• Severe symptoms: Monitor sodium every 2 hours during initial correction 1, 3
• Mild symptoms: Monitor sodium every 4 hours 1
• Chronic hyponatremia: Monitor daily to ensure correction does not exceed 8 mmol/L in 24 hours 1

---

Common Pitfalls to Avoid

• Never use fluid restriction in cerebral salt wasting (CSW)—this worsens outcomes 1, 3
• Distinguish SIADH (euvolemic, treat with fluid restriction) from CSW (hypovolemic, treat with volume and sodium replacement) 1, 3
• Never use hypertonic saline in hypervolemic hyponatremia without life-threatening symptoms 1
• Failing to recognize and treat the underlying cause leads to poor outcomes 1, 3
• Inadequate monitoring during active correction risks osmotic demyelination 1
• Even mild hyponatremia (130-135 mmol/L) increases fall risk (21% vs 5% in normonatremic patients) and mortality 1, 2